Residual DCIS Versus No Residual Breast Tumor After Neoadjuvant Chemotherapy in ypN0 Breast Cancer: A Retrospective Clinical, MRI, and Survival Comparison
7 affiliations
- 1Department of Radiation Oncology, University of Health Sciences Turkey, Istanbul Training and Research Hospital, 34098 Istanbul, Turkey
- 2Department of Medical Oncology, University of Health Sciences Turkey, Istanbul Training and Research Hospital, 34098 Istanbul, Turkey
- 3Department of Nuclear Medicine, University of Health Sciences Turkey, Istanbul Training and Research Hospital, 34098 Istanbul, Turkey
- 4Department of Pathology, University of Health Sciences Turkey, Istanbul Training and Research Hospital, 34098 Istanbul, Turkey
- 5Department of Radiology, University of Health Sciences Turkey, Istanbul Training and Research Hospital, 34098 Istanbul, Turkey
- 6Department of General Surgery, University of Health Sciences Turkey, Istanbul Training and Research Hos pital, 34098 Istanbul, Turkey
- 7Department of General Surgery, School of Medicine, Bahçeşehir University, 34734 Istanbul, Turkey
Abstract
Background/Objectives: The prognostic significance of residual ductal carcinoma in situ (ypTis) compared with no residual tumor in the breast (ypT0) after neoadjuvant chemotherapy (NAC) remains uncertain. We compared clinicopathological, MRI, treatment, and survival outcomes between these groups. Methods: This single-center retrospective study included consecutive patients with stage II–III breast cancer who achieved ypN0 and ypT0/is status after NAC and definitive surgery between 2019 and 2023. Univariable and multivariable logistic regression analyses were performed to identify factors associated with ypTis. DFS and OS were assessed using Kaplan–Meier analysis and log-rank tests. Results: Among 175 patients, 139 (79.4%) had ypT0 and 36 (20.6%) had ypTis. Median follow-up was 51 months. Clinical T-stage distribution differed significantly between groups (p = 0.010), with cT4 disease in 13.9% of ypTis versus 2.2% of ypT0 patients. HER2 positivity and MRI-detected satellite foci were more frequent in the ypTis group. In multivariable analysis, HER2 positivity (OR 2.50, 95% CI 1.05–5.93; p = 0.038), and MRI-detected satellite foci (OR 2.41, 95% CI 1.12–5.16; p = 0.024) were associated with ypTis. Local recurrence occurred in 3/36 (8.3%) ypTis and 1/139 (0.7%) ypT0 patients. DFS did not differ significantly between groups (5-year estimates: 78.7% vs. 78.9%; p = 0.860). OS also showed no significant difference (5-year estimates: 96.8% vs. 87.3%; p = 0.320). Conclusions: Residual DCIS was not associated with statistically significant differences in DFS or OS following NAC. However, these findings do not establish prognostic equivalence and should be interpreted cautiously given the limited number of ypTis patients and outcome events.
Related
- Predicting Four-Class Residual Cancer Burden (RCB) Before Neoadjuvant Chemotherapy in Breast Cancer: Block-Structured Model Comparison, Selection Criterion and Decision Threshold
- Tumor Clusterin Expression at Diagnosis Is Associated with Residual Disease Burden After Neoadjuvant Chemotherapy in Breast Cancer
- Pretreatment Body Composition and Its Association with Pathologic Complete Response and Survival in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Retrospective Cohort Study
- Fusion of Deep Learning Radiomics and Clinical Features for Individualized Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma
- Efficacy comparison of neoadjuvant chemotherapy, chemoradiotherapy, and chemoimmunotherapy in resectable esophageal squamous cell carcinoma: short- and long-term outcomes from a propensity score-matched analysis
BibTeX
@article{mermut2026residual,
title = {{Residual DCIS Versus No Residual Breast Tumor After Neoadjuvant Chemotherapy in ypN0 Breast Cancer: A Retrospective Clinical, MRI, and Survival Comparison}},
author = {Özlem Mermut and Berrin Yalçın and Rıza Umar Gürsu and Esra Arslan and Semiha Battal Havare and Emine Sevcan Ata and Merve Büşra Cengiz Gökmen and Didem Can Trabulus},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18213491},
url = {https://www.mdpi.com/2072-6694/18/21/3491},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Residual DCIS Versus No Residual Breast Tumor After Neoadjuvant Chemotherapy in ypN0 Breast Cancer: A Retrospective Clinical, MRI, and Survival Comparison
AU - Özlem Mermut
AU - Berrin Yalçın
AU - Rıza Umar Gürsu
AU - Esra Arslan
AU - Semiha Battal Havare
AU - Emine Sevcan Ata
AU - Merve Büşra Cengiz Gökmen
AU - Didem Can Trabulus
PY - 2026
DA - 2026/10/29
JO - Cancers
DO - 10.3390/cancers18213491
UR - https://www.mdpi.com/2072-6694/18/21/3491
AB - Background/Objectives: The prognostic significance of residual ductal carcinoma in situ (ypTis) compared with no residual tumor in the breast (ypT0) after neoadjuvant chemotherapy (NAC) remains uncertain. We compared clinicopathological, MRI, treatment, and survival outcomes between these groups. Methods: This single-center retrospective study included consecutive patients with stage II–III breast cancer who achieved ypN0 and ypT0/is status after NAC and definitive surgery between 2019 and 2023. Univariable and multivariable logistic regression analyses were performed to identify factors associated with ypTis. DFS and OS were assessed using Kaplan–Meier analysis and log-rank tests. Results: Among 175 patients, 139 (79.4%) had ypT0 and 36 (20.6%) had ypTis. Median follow-up was 51 months. Clinical T-stage distribution differed significantly between groups (p = 0.010), with cT4 disease in 13.9% of ypTis versus 2.2% of ypT0 patients. HER2 positivity and MRI-detected satellite foci were more frequent in the ypTis group. In multivariable analysis, HER2 positivity (OR 2.50, 95% CI 1.05–5.93; p = 0.038), and MRI-detected satellite foci (OR 2.41, 95% CI 1.12–5.16; p = 0.024) were associated with ypTis. Local recurrence occurred in 3/36 (8.3%) ypTis and 1/139 (0.7%) ypT0 patients. DFS did not differ significantly between groups (5-year estimates: 78.7% vs. 78.9%; p = 0.860). OS also showed no significant difference (5-year estimates: 96.8% vs. 87.3%; p = 0.320). Conclusions: Residual DCIS was not associated with statistically significant differences in DFS or OS following NAC. However, these findings do not establish prognostic equivalence and should be interpreted cautiously given the limited number of ypTis patients and outcome events.
SN - 2072-6694
ER -